Atai Beckley Inc.

NASDAQ:ATAI

Biotechnology

Healthcare
$7.35 -1.35%

-$0.06 today

Market cap
$2.72B
Beta
1.60
P/E (TTM)
-1.4
EPS (TTM)
-$2.93
52W Low $2.00High $6.75

Volume 0.00M

Average 5.68M

ATAI Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Atai Beckley Inc.NASDAQ: ATAI

Revenue · Q2 FY2026 · quarter ended Jun 2026

Revenue growth accelerates

Q2 FY2026 revenue of $1.7M rose 137.0% year over year, ahead of the +93.7% change in trailing-twelve-month revenue. Sequentially, it rose 78.6% from the prior quarter. Over 3 fiscal years it compounded at +159.9% a year.

Context

  • Revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 9 analysts of $2.15M (-47.4%) for the fiscal year ending Dec 2026, a slowdown from the +1227.6% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$1.7M+78.6% QoQ
Last fiscal yearDec 2025
$4.09M+1227.6% YoY
LTMJun 2026
$4.47M+93.7% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+137.0%-59.9%-196.9 pp
1 year+1227.6%-47.4%-1275.0 pp
3-year CAGR+159.9%-25.6%-185.5 pp
5-year CAGR+120.9%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
4.09M USD
Year-over-year change
+1227.6%
4-year CAGR
-33.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How ATAI compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Its year-over-year change of +93.7% is the 4th highest of 8, against a peer median of +23.9%.
  • Over three fiscal years its annual growth of +159.9% compares with a peer median of -16.0%.
ATAI Competitors
Revenue for ATAI and competitors
Company Period LTM YoY 3-year CAGR
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$217.17M USD+396.7%—
NKTRNektar TherapeuticsLTM Jun 2026$54.59M USD-27.2%-15.7%
IMTXImmatics N.V.LTM Mar 2026€37.3M EUR-74.1%-34.6%
RLAYRelay Therapeutics, Inc.LTM Jun 2026$10.35M USD+23.9%+123.2%
ATAIAtai Beckley Inc.LTM Jun 2026$4.47M USD+93.7%+159.9%
DNTHDianthus Therapeutics, Inc.LTM Jun 2026$1.9M USD-60.8%-31.8%
INBXInhibrx Biosciences, Inc.LTM Mar 2026$1.3M USD+550.0%-16.0%
ELVNEnliven Therapeutics, Inc.LTM Sep 2026$0 USD——
AMLXAmylyx Pharmaceuticals, Inc.LTM Sep 2026$0 USD+100.0%—
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$0 USD——
SANASana Biotechnology, Inc.LTM Mar 2026$0 USD——
Peer median (excluding ATAI) —+23.9%-16.0%

Competitors are the stored peer set for ATAI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue20.38M233K314K308K4.09M
Cost of Revenue47K168K319K473K1.01M
Gross Profit20.33M65K(5K)(165K)3.08M
Gross Margin99.8%27.9%-1.6%-53.6%75.3%
Research & Development47.91M74.15M61.88M54.98M53.06M
Selling, General & Admin92.75M70.35M63.58M47.54M49.78M
Operating Expenses140.65M144.5M125.47M102.53M102.84M
Depreciation & Amortization47K168K319K473K1.01M
EBITDA(178.19M)(150.1M)(39.9M)(147.33M)(657.68M)
EBITDA Margin-874.5%-64419.3%-12708.3%-47835.4%-16084.0%
Operating Income(120.33M)(144.43M)(125.47M)(102.69M)(99.76M)
Operating Margin-590.5%-61987.1%-39958.9%-33341.2%-2439.7%
Interest Income205K548K1.85M778K1.48M
Interest Expense0923K2.66M3.12M1.16M
Other Income / Expenses(57.91M)(6.76M)82.59M(48.24M)(560.09M)
Income Before Tax(178.23M)(151.19M)(42.88M)(150.93M)(659.85M)
Pre-Tax Margin-874.7%-64887.6%-13655.7%-49003.2%-16137.2%
Income Tax Expense(3.99M)6.23M1.02M(881K)298K
Net Income(167.81M)(152.39M)(40.22M)(149.27M)(660.05M)
Net Margin-823.6%-65401.3%-12810.2%-48464.0%-16142.0%
EPS (Basic)(1.04)(0.98)(0.25)(0.93)(2.91)
EPS (Diluted)(1.04)(0.98)(0.25)(0.93)(2.91)
Weighted Avg Shares160.68M155.72M158.83M160.16M226.53M
Weighted Avg Shares (Diluted)160.68M155.72M158.83M160.16M226.53M

Atai Beckley Inc.

NASDAQ:ATAI

Intrinsic Alpha fair value

Locked

Current Price

$7.35

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.